Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab plus retifanlimab or tebotelimab in first-line recurrent or metastatic squamous cell carcinoma of the head and neck
2020-004918-35Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of enoblituzumab in head and neck squamous cell carcinoma (HNSCC) and head and neck cancer (HNC) (2 arms), sponsored by MacroGenics. Primary endpoint: Efficacy of enoblituzumab plus retifanlimab. Started Feb 2021; status: terminated.
02
Drugs
enoblituzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2020-004918-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004918-35.